Skip to main content

APO-NEBIVOLOL, NEBIVOLOL APOTEX (Apotex Pty Ltd)

Product name
APO-NEBIVOLOL, NEBIVOLOL APOTEX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
143 working days (255)
Active ingredients
nebivolol (as hydrochloride)
Registration type
New generic medicine
Indication

APO-NEBIVOLOL, NEBIVOLOL APOTEX (tablets) is indicated for the treatment of:

  • essential hypertension;
  • stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

Help us improve the Therapeutic Goods Administration site